Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S272400, C548S252000, C548S264200
Reexamination Certificate
active
07960422
ABSTRACT:
Compounds of formula (I)wherein R1isas well as pharmaceutically acceptable salts, hydrates and/or enantiomers thereof are useful as compounds that exhibit activity at metabotropic glutamate receptors.
REFERENCES:
patent: 4663332 (1987-05-01), Carson et al.
patent: WO-93-02677 (1993-02-01), None
patent: WO-01-85705 (2001-11-01), None
patent: WO-03-002559 (2003-01-01), None
patent: WO-03-020721 (2003-03-01), None
patent: WO-03/029210 (2003-04-01), None
patent: WO-03/077918 (2003-09-01), None
patent: WO-2004/014881 (2004-02-01), None
patent: WO-2005/077345 (2005-08-01), None
patent: WO-2005/080356 (2005-09-01), None
patent: WO-2005/080379 (2005-09-01), None
patent: WO-2005/080386 (2005-09-01), None
patent: WO-2006/014185 (2006-02-01), None
patent: WO-2007/040982 (2007-04-01), None
patent: WO-2007/130820 (2007-11-01), None
patent: WO-2007/130823 (2007-11-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18.
STN International; file CAPLUS; AN:2003:396864 (WO 03042188 A1).
Schoepp et al., Trends Pharmacol. Sci. 14:13 (1993).
Schoepp, Neurochem. Int. 24:439 (1994).
Pin et al., Neuropharmacology 34:1 (1995).
Bordi and Ugolini, Prog. Neurobiol. 59:55 (1999).
Nakanishi, Neuron 13:1031 (1994).
Knopfel et al., J. Med. Chem. 38:1417 (1995).
Pin et al., PNAS 89:10331 (1992).
Minakami et al., BBRC 199:1136 (1994).
Joly et al., J. Neurosci. 15:3970 (1995).
Baskys, Trends Pharmacol. Sci. 15:92 (1992).
Watkins et al., Trends Pharmacol. Sci. 15:33 (1994).
Bashir et al., Nature 363:347 (1993).
Bortolotto et al., Nature 368:740 (1994).
Aiba et al., Cell 79:365 (1994).
Aiba et al., Cell 79:377 (1994).
Meller et al., Neuroreport 4:879 (1993).
Bordi and Ugolini, Brain Res. 871:223 (2000).
Cunningham et al., Life Sci. 54:135 (1994).
Hollman et al., Ann. Rev. Neurosci. 17:31 (1994).
Spooren et al., Trends Pharmacol. Sci. 22:331 (2001).
Gasparini et al.Curr. Opin. Pharmacol. 2:43 (2002).
NeugebauerPain98:1 (2002).
Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535.
Janet Hoogstraate, PhD “Pharmacokinetic screening following single intravenous and oral dosing in rats”, Research DMPK, AstraZeneca R&D Sodertalje Mar. 15, 2006.
Opposition, Costa Rica Patent Application No. 11.376, dated Oct. 26, 2010.
Arzel Erwan
Edwards Louise
Isaac Methvin
McLeod Donald A.
Slassi Abdelmalik
Astrazeneca AB
Connolly Bove & Lodge & Hutz LLP
Willis Douglas M
Wilson James O
LandOfFree
Pharmaceutically active compounds containing tetrazolyl and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically active compounds containing tetrazolyl and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active compounds containing tetrazolyl and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719236